Literature DB >> 6183460

Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy.

S Furuya, Y Kumamoto, E Yokoyama, T Tsukamoto, T Izumi, Y Abiko.   

Abstract

In order to examine to what extent adrenergic mechanism contributes to the urethral pressure in patients with benign prostatic hypertrophy, changes in the intraurethral pressure in the prostatic zone were measured in vivo by both the urethral pressure profile technique and the balloon method before and after administration of alpha-adrenergic stimulants and an alpha-adrenergic blocker. The effect of spinal anesthesia on the urethral pressure was also investigated. It is suggested that 40 per cent of the total urethral pressure in patients with benign prostatic hypertrophy is due to alpha-adrenergic tone, and the remaining 53 per cent is due to static pressure resulting from the hypertrophied prostatic bulk. The in vitro study indicates that the increase in urethral pressure and contraction of the prostate, prostatic capsule and prostatic urethra.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183460     DOI: 10.1016/s0022-5347(17)53216-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  Effects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate.

Authors:  Y Homma; K Hamada; Y Nakayama; G Tsujimoto; K Kawabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.

Authors:  J L Pool; R S Kirby
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans.

Authors:  K Harada; M Ohmori; A Fujimura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

Review 5.  Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory.

Authors:  Kaori Ito; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-10-17       Impact factor: 4.335

Review 6.  Subtypes of functional alpha1-adrenoceptor.

Authors:  James R Docherty
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

7.  A placebo controlled double blind study using perioperative prazosin in the prevention of urinary retention following inguinal hernia repair.

Authors:  H H Woo; H L Carmalt
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 8.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

9.  Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.

Authors:  F Lefèvre-Borg; S E O'Connor; H Schoemaker; P E Hicks; J Lechaire; E Gautier; F Pierre; C Pimoule; P Manoury; S Z Langer
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

Review 10.  Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.